When analyzing carcinomas stratified only by the presence of activating mutations in the PI3K-AKT pathway, regardless of the tumor HER2 status, we found that the presence of such a mutation was associated with a lower ERBB2 expression (p = 0.0002). The gene discussed is ERBB2; the disease is carcinoma.